Siow Ming Lee

Consultant/Professor of Medical Oncology

University College London Hospitals NHS Foundation Trust

United Kingdom

Research Interests

Explore related searches

Professors in United Kingdom

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Siow Ming Lee is a Consultant and Professor of Medical Oncology at University College London Hospitals NHS Foundation Trust, UK. His research areas include the effectiveness of COVID-19 vaccinations in cancer patients, as well as advancements in the treatment and profiling of non-small cell lung cancer. Recent articles authored by him address critical issues such as vaccine response association with infection severity and the optimization of molecular profiling techniques.

Articles (7)

Year:

2023

Year:

2022

Year:

2022

Year:

2021

Year:

2020

Year:

2020

Year:

2020

Collaborators (5)

Francesca Holt

University of Oxford

UNITED KINGDOM

View details

Laura Feeney

The Queen's University Belfast

UNITED KINGDOM

View details

Csilla Varnai

University of Birmingham

UNITED KINGDOM

View details

Piangfan Naksukpaiboon

University of Birmingham

UNITED KINGDOM

View details

Tim Robinson

University of Bristol

UNITED KINGDOM

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Siow Ming Lee

Research Interests

Explore related searches

Contact this professor

About

Articles (7)

Association of SARS-CoV-2 Spike Protein Antibody Vaccine Response With Infection Severity in Patients With Cancer A National COVID Cancer Cross-sectional Evaluation

COVID-19: Third dose booster vaccine effectiveness against breakthrough coronavirus infection, hospitalisations and death in patients with cancer: A population-based study

Vaccine effectiveness against COVID-19 breakthrough infections in patients with cancer (UKCCEP): a population- based test-negative case-control study

Optimising fusion detection through sequential DNA and RNA molecular profiling of non-small cell lung cancer

COVID-19 prevalence and mortality in patients with cancer and the effect of primary tumour subtype and patient demographics: a prospective cohort study

Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC

Pembrolizumab in patients with non-small-cell lung cancer of performance status 2 (PePS2): a single arm, phase 2 trial

Collaborators (5)

Francesca Holt

Laura Feeney

Csilla Varnai

Piangfan Naksukpaiboon

Tim Robinson

Make your next move.